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Abstract
Background: Early diagnosis of HIV infection can prevent morbidity and mortality as well as reduce HIV
transmission. The aim of the present study was to assess prevalence, describe trends and identify factors associated
with late presentation of HIV infection in Barcelona (Spain) during the period 2001-09.
Methods: Demographic and epidemiological characteristics of cases reported to the Barcelona HIV surveillance
system were analysed. Late presentation was defined for individuals with a CD4 count below 350 cells/ml upon
HIV diagnosis or diagnosis of AIDS within 3 months of HIV diagnosis. Multivariate logistic regression were used to
identify predictors of late presentation.
Results: Of the 2,938 newly diagnosed HIV-infected individuals, 2,507 (85,3%) had either a CD4 cell count or an
AIDS diagnosis available. A total of 1,139 (55.6%) of the 2,507 studied cases over these nine years were late
presenters varying from 48% among men who have sex with men to 70% among heterosexual men. The
proportion of late presentation was 62.7% in 2001-2003, 51.9% in 2004-2005, 52.6% in 2006-2007 and 52.1% in
2008-2009. A decrease over time only was observed between 2001-2003 and 2004-2005 (p = 0.001) but remained
constant thereafter (p = 0.9). Independent risk factors for late presentation were older age at diagnosis (p <
0.0001), use of injected drugs by men (p < 0.0001), being a heterosexual men (p < 0.0001), and being born in
South America (p < 0.0001) or sub-Saharan Africa (p = 0.002).
Conclusion: Late presentation of HIV is still too frequent in all transmission groups in spite of a strong
commitment with HIV prevention in our city. It is necessary to develop interventions that increase HIV testing and
facilitate earlier entry into HIV care.
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Introduction
In the European Union it is estimated that 15-38% of
cases of HIV infection are diagnosed late [1] and 30% of
infected individuals are not aware of their serological
status, with proportions that vary between 12% and 20%
in Sweden to more than 50% in Poland [2]. In Spain
56.3% of new diagnoses of HIV infection between 2003
and 2007 required treatment (CD4 < 350 cells/μl) at the
time of diagnosis and 30.2% of these presented severe
immunosuppression (CD4 < 200 cells/μl) [3].
Reducing the time elapsed between infection and the
initiation of antiretroviral therapy (ART) is important to
decrease progression of the infection and to facilitate
immunological recovery. Therefore, early identification
of infected individuals has been a priority of most AIDS
prevention and control programs since the beginning of
AIDS epidemic [4-6].
Delays in HIV care have serious public health implica-
tions because opportunities to prevent further transmis-
sion through effective ART are lost [7,8], and because
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stage leads to poorer treatment outcomes than with
early treatment [9,10]. Also, some studies have shown
that after HIV infection diagnosis, most infected indivi-
duals remain sexually active, although most use safer
practices, thereby limiting infection spread [11-13]. Late
diagnosis of HIV also has economic implications for
health services and society [14-16].
In Spain, all citizens enjoy universal free access to
health services and ART is available for all patients.
Delayed diagnosis and access to ART is essentially a
public health problem and a loss of opportunity to limit
the progression of disease and reduce the transmission
of infection. For this reason, the objective of the present
study was to determine the frequency of individuals pre-
senting for care with a CD4 count below 350 cells/μlo r
presenting with an AIDS-defining event, to evaluate
trends in this proportion, and to identify factors asso-
ciated with late presentation of HIV infection in Barce-
lona during the period 2001-09.
Methods
The city of Barcelona (1.6 million inhabitants), is located
in the northern part of the east coast of Spain. In 2001,
11.89 AIDS cases and 17.47 cases of HIV infections
were registered per 100,000 inhabitants. This figures
decreased to 5.9 AIDS cases and 16.7 HIV infections in
2009. The Barcelona AIDS Surveillance System, which
has been active since 1987, is an active system that col-
lects data provided by doctors, hospital discharges, the
tuberculosis (TB) register, and mortality databases
regarding patients diagnosed with AIDS. The voluntary
HIV Surveillance System, which has been active since
2001, collects information about new diagnoses of HIV
infection in individuals older than 13 years tested in
public or private facilities. All AIDS cases were collected
through Barcelona AIDS Surveillance, and all HIV cases
from the voluntary HIV Surveillance system.
Clinicians complete a standard data collection form
and use a unique patient identifier code [17].
In this study, we considered all new diagnoses of HIV
infection or of AIDS within 3 months of a positive HIV
test among individuals older than 13 years who were
resident in Barcelona during the period 2001-09. These
cases of AIDS and HIV infection met the relevant cri-
teria of the European Centre for AIDS/HIV Epidemiolo-
gical Surveillance[18].
We analysed demographic data (sex, date and country
of birth, year of arrival in Spain), HIV exposure category
(injecting drug users [IDU], sex between men [MSM],
heterosexuals [HT]), calendar period of HIV diagnosis
(subdivided into 4 periods: 2001-03, 2004-05, 2006-07
and 2008-09), clinical data (AIDS, absolute CD4+ [CD4]).
According to the new European definition[19], late
presenters (LP) was defined for persons presenting for
care with a CD4 count below 350 cells/μlo rp r e s e n t i n g
with an AIDS-defining event at the time of HIV diagno-
sis or within 3 months of the HIV-positive test, regard-
less of the CD4 cell count. Other patients were
classified as non-late presenters.
Statistical analyses
A descriptive analysis of the epidemiological characteris-
tics of cases of HIV infection defined as late presenters
was carried out.
For categorical and continuous variables, we compared
the count (proportion) and median (interquartile range
-IQR-), respectively, of late presenters to non late pre-
senters. Categorical variables were compared using c
2
test. For each comparison, the univariate odds ratio
(OR), 95% confidence interval (CI) and p-value for sta-
tistical significance were computed. Continuous vari-
ables were compared using the Mann-Whitney U test or
the Kruskal-Wallis test. Trends in LP over time were
analysed using the c
2 test for trend in proportions. Mul-
tivariate logistic regression was used to identify predic-
tors of late presentation. A p-value of < 0.05 was
considered to be statistically significant. Statistical ana-
lyses were performed using SPSS for Windows (Version
18.0; SPSS, Chicago, IL).
A l ld a t aw e r ec o l l e c t e db yt h eH I V / A I D SR e g i s t r yo f
B a r c e l o n aC i t ya n dw e r eh a n d led in a strictly confiden-
tial manner according to the requirements of Spanish
data protection Law[20].
Results
During the study period, 2,938 new cases of HIV infec-
tion were detected, of which 2,268 (76.2%) were
detected in hospital and 670 (22.8%) in non-hospital set-
tings. The majority of cases were male (83.3%), with a
median age of 35 years, MSM (51.8%) and 19.9% pre-
sented with AIDS. The most common AIDS-defining
conditions were TB (26.2%), Pneumocystis jirovecii
pneumonia (24.3%) and Kaposi Sarcoma (10.3%). In 90%
of cases the AIDS diagnosis was made within 30-days of
HIV infection. We observed that the proportion of IDU
among males decreased during the study period (p <
0.0001), whereas the proportion of MSM increased from
40.2% in 2001-03 to 61.9% in 2008-09 (p < 0.0001).
However, no significant trend was observed in IDU and
HT women (p = 0.1 y p = 0.2, respectively) (Table 1).
55% of cases were born in Spain. The proportion of
migrants increased from 22.6% in 2001-03 to 45.8% in
2008-09 (p < 0.0001), of which 37.8% had been resident
in Spain for less than 1 year, 38.8% between 2 and 5
years and 8.3% more than 10 years.
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available for 85.3% (2,507) of the 2,938 newly diagnosed
HIV-infected individuals. Patients whose CD4 cell count
was not available differed from those for whom CD4
count was available in the frequency of IDU (26.0% vs
12.9%, p < 0.001) and in the median age (34.43 years vs
37.39 years, p < 0.001).
The proportion of patients who were LP was 55.6%
(1,393 persons) and 38.5% had advanced HIV infection
(15.2% presenting with CD4 < 200 cell//μla n d2 3 . 3 %
with AIDS regardless of the CD4 cell count). A decrease
of LP over time only was observed from 62.7% in 2001-
03 to 51,9% in 2004-05 (p = 0.001), but remained con-
stant thereafter (p = 0.9). Figure 1 shows the proportion
of individual by CD4 count/AIDS at the time of HIV
diagnosis according to category of exposure: 48% of
MSM had < 350 CD4/μl, whereas among IDU men and
HT men this percentage was 66% and 70%, respectively.
LP was slightly, but not significantly, more frequent
among women than among men (58.5% vs 55.0%). How-
ever, differences were observed according to age, region
of birth, category of exposure and period of diagnosis
(Table 2). The logistic regression model showed that
risk of LP was associated with age: for each increment
of 5 years, risk of being a late presenter increased by
38%; with region of birth: LP was significantly more
common among individuals born in Latin America and
Caribbean (OR:1.48; CI: 1.20-1.83) and Sub-Saharan
Africa (OR:2.43; CI: 1.14-4.17) than among individuals
born in Spain; with category of exposure and sex: IDU
and HT men showed an OR for risk of being LP of 2.12
(1.57-2.87) and 1.79 (1.38-2.34), respectively, compared
Table 1 Characteristics of newly diagnosed HIV-infected patients in Barcelona (Spain), 2001-2009
Characteristics 2001-2003;n = 956
(100%)
2004-2005;n = 630
(100%)
2006-2007;n = 691
(100%)
2008-2009; n = 661
(100%)
Total; N = 2938
(100%)
Sex
Male 768 (80.3) 502 (79.7) 599 (86.7) 581 (87.9) 2450 (83.4)
Female 188 (19.3) 128 (20.3) 92 (13.3) 80 (12.1) 488 (16.6)
Age at HIV diagnosis*
All 35.1 (29.8-42.9) 34.7 (28.9-41.7) 35.5 (29.9-43.1) 34.3 (29.2-41.1) 35.0 (29.4-42.2)
Male 35.2 (29.8-42.8) 34.8 (29.3-41.6) 35.5 (29.8-42.7) 34.2 (29.0-40.8) 35.1 (29.5-35.1)
Female 34.5 (29.8-42.9) 36.7 (27.4-42.1) 35.9 (30.0-44.9) 35.3 (29.3-44.8) 34.5 (29.3-43.4)
Region of birth
Spain 551 (57.6) 353 (56.0) 368 (53.3) 344 (52.0) 1616 (55.0)
Western Europe & North
America
53 (5.5) 30 (4.8) 53 (7.7) 54 (8.2) 190 (6.5)
Latin America & Caribbean 147 (15.4) 133 (21.1) 191 (27.6) 178 (26.9) 649 (22.1)
Middle East & North Africa 22 (2.3) 7 (1.1) 12(1.7) 9(1.4) 50(1.7)
Sub-Saharan Africa 30 (3.1) 33 (5.2) 20 (2.9) 20 (3.0) 103 (3.5)
Eastern Europe 14 (1.5) 12 (1.9) 20 (2.9) 36 (5.4) 82 (2.8)
Asia 6 (0.6) 6 (1.0) 1 (0.1) 6 (0.9) 19 (0.6)
unknown 133 (13.9) 56 (8.9) 26 (3.8) 14 (2.1) 229 (7.8)
Exposure category by
sex**
IDU men 181 (18.9) 65 (10.3) 52 (7.5) 29 (4.4) 327 (11.1)
MSM 384 (40.2) 320 (50.8) 410 (59.3) 409 (61.9) 1523 (51.8)
HT men 149 (15.6) 85 (13.5) 93 (13.5) 87 (13.2) 414 (14.1)
IDU women 48 (5.0) 22 (3.5) 10 (1.4) 12 (1.8) 92 (3.1)
HT women 129 (13.5) 102 (16.2) 74 (10.7) 54 (8.2) 359 (12.2)
unknown 65 (6.8) 36 (5.7) 52 (7.5) 70 (10.6) 223 (7.6)
CD4 cell count and AIDS
AIDS 241 (25.2) 105 (16.7) 138 (20.0) 100 (15.1) 584 (19.9)
< 200 141 (14.7) 78 (12.4) 81 (11.7) 74 (11.2) 374 (12.7)
200-349 123 (12.9) 96 (15,2) 100 (14,5) 116 (17.5) 435 (14.8)
350-499 111 (11,6) 92 (14.6) 117 (16.9) 108 (16.3) 428 (14.6)
500 and more 189 (19.8) 167 (26.5) 171 (24.7) 159 (24.1) 686 (23.3)
unknown (%) 151 (15.8) 92 (14.6) 84 (12.2) 104 (15.7) 431 (14.7)
*Median (interquartile range). **IDU: injection drug use; MSM: men who have sex with men; HT: heterosexual contact.
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observed in the last three periods compared to the per-
iod 2001-03 (Table 2).
In 650 (33.8%) cases of the 1,923 new diagnoses of
HIV infection with CD4 count data and without AIDS
the median time elapsed between the diagnosis of infec-
tion and the first determination of CD4 was 56 days
(15-129), with differences according to category of expo-
s u r e .A m o n gI D U ,t h em e d i a nt i m ei n t e r v a lw a s1 6 2
days (40-495), while for other exposures it was 54 days
(14-115) (p = 0,002).
Discussion
This study shows that a high proportion of individuals
(55.6%) meet the criteria of the new European definition
of LP (CD4 < 350 cells/μl or AIDS). Although it is diffi-
cult to obtain data on LP in large cities, these figures do
not differ greatly from those observed at national or
regional level, even in areas where the prevention of
HIV infection is a priority [1,3,21,22]. Thus, 50% of new
diagnoses of HIV infection occur when the subject
needs treatment [23]. If we take into account the new
ARV treatment recommendations, which indicate that
treatment should be started in asymptomatic patients
with CD4 < 500 cells/μl, this proportion reaches 70%
[24-26]. These high proportions of patients with “care-
stage” HIV infection at their initial clinic visit suggests
that barriers to HIV care are also considerable in devel-
oped countries. The negative impact of LP is a likely
increase in morbidity and mortality [27,28], more poten-
tial transmission at the community level [13] and further
treatment costs [14-16].
The proportion of LP decreased only between 2001-03
and 2004-05, as has been observed in other studies
[3,29], it continues to be high in all groups. LP is asso-
ciated with age and affects all subpopulations, although
its distribution is not homogeneous [3,30]
. The limited
perception of risk [31] compounds the fact that tests
tend to be offered less frequently to older individuals.
Heterosexual individuals over 50 years are not the target
of most prevention campaigns [32]. In general, indivi-
duals born outside Spain presented greater risk of LP
0%1 0%2 0% 30%4 0% 50% 60%7 0% 80% 90%1 00%
Total
MSM
HTm
HTw
IDUm
IDUw
Figure 1 Proportion of individual by CD4 count/AIDS at the time of HIV diagnosis according to sex and category of exposure in
Barcelona (Spain): 2001-2009. IDUw: injection drug use women; IDUm: injection drug use men; HTw: heterosexual women; HTm: heterosexual
men; MSM: men who have sex with men.
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Latin America and Sub-Saharan Africa, as observed in
other studies [3,10]. In a study carried out in Italy, a
greater proportion of LP was also observed in the immi-
grant population [29].
In relation to sex and the mechanism of transmission,
it was observed that IDU men and HT men presented a
higher frequency of LP compared to MSM. This higher
proportion of delayed diagnoses among heterosexuals
compared to cases of homosexual transmission has been
highlighted in various studies [33-35]. A greater prob-
ability of delayed diagnosis has been observed in Italy,
but only in drug addicts that remained isolated from
social and health services [36]. However in our study,
comparing the MSM group with IDU women or HT
women this difference disappears. This may be due to
women’s higher perception of risk, their greater likeli-
hood of attending health services [37] and the probabil-
ity that they will be offered the test during pregnancy or
birth, as a result of which they will be diagnosed earlier
than HT or IDU men.
Some results of this study suggest that the delay
among IDU is more a delay in beginning treatment than
in diagnosis of the infection, since they are often diag-
nosed in drug rehabilitation centres or in prison. In this
sense, the overrepresentation of IDU without lympho-
cyte count data would indicate that the diagnostic test is
carried out on these individuals, but many are lost to
follow-up. Moreover, the median time elapsed between
the diagnosis of infection and the determination of CD4
was notably higher among the IDU (162 days) compared
to other categories of exposure (54 days), which would
indicate that the delay in this group was more likely due
to a delay in beginning treatment than delayed diagno-
sis, as observed in other studies [38,39]. Consequently,
public health strategies aimed at ensuring access to
health resources are a priority for diminishing LP in this
group. An early diagnosis, especially in this group does
Table 2 Characteristics and factors associated with late presentation for newly HIV diagnosis in Barcelona (Spain),
2001-2009
Characteristics Total N = 2507 Late presenters (%) Unadjusted OR (CI) p value Adjusted OR (CI) p value
Sex
Male 2097 1153 (55.0) 1 0.18
Female 410 240 (58.5) 1.16 (0.93-1.44)
Age at HIV diagnosis*
All 35.4 (29.6-42.8) 37.9 (31.5-46.2) 0.0001 1.38 (1.27-1.40) <0.0001
Male 35.4 (29.7-42.5) 38.0 (31.8-45.8)
Female 35.3 (29.4-44.4) 37.7 (30.6-47.2)
Age (per a 5 yrs increase)
Region of birth
Spain 1460 826 (56.6) 1 0.002 1 0.279
Western Europe & North America 166 73 (44.0) 0.60 (0.43-0.84) 0.2 0.83 (0.59-1.16) < 0.0001
Latin America & Caribbean 570 315 (55.3) 0.95 (0.78-1.16) 0.8 1.48 (1.20-1.83) 0.838
Middle East & North Africa 44 26 (59.1) 1.11 (0.58-2.13) 0.02 1.07 (0.56-2.03) 0.002
Sub-Saharan Africa 74 52 (70.3) 1.81 (1.08-3.12) 0.9 2.43 (1.14-4.17) 0.274
Eastern Europe 64 36 (56.3) 0.99 (0.58-1.68) 0.2 1.35 (0.79-2.31) 0.219
Asia 18 13 (72.2) 2.00 (0.66-6.44) 0.05 1.96 (0.67-5.74) 0.107
unknown 111 52 (46.8) 0.68 (0.45-1.01) 0.71 (0.47-1.07)
Exposure category**
MSM 1333 636 (47.7) 1 < 0.001 1 < 0.0001
IDU men 252 166 (65.9) 2.12 (1.58-2.83) < 0.001 2.12 (1.57-2.87) < 0.0001
HT men 382 269 (70.4) 2.61 (2.03-3.36) 0.9 1.79 (1.38-2.34) 0.340
IDU women 62 34 (54.8) 1.33 (0.78-2.29) 0.004 1.29 (0.76-2.20) 0.279
HT women 319 181 (56.7) 1.44 (1.12-1.85) < 0.001 1.16 (0.88-1.51) 0.009
unknown 159 107 (67.3) 2.26 (1.57-3.24) 1.63 (1.13-2.37)
Year of diagnosis
2001-2003 805 505 (62.7) 1 < 0.001 1 0.001
2004-2005 538 279 (51.2) 0.64 (0.51-0.80) < 0.001 0.67 (0.53-0.85) 0.001
2006-2007 607 319 (52.6) 0.66 (0.53-0.82) < 0.001 0.67 (0.53-0.85) 0.001
2008-2009 557 290 (52.1) 0.65 (0.52-0.81) 0.71 (0.56-0.90)
*Median (interquartile range). **IDU: injection drug use; MSM:men who have sex with men; HT:heterosexual contact.
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follow-up or treatment [40,41]. However, reinforcing the
strategies that increase the availability of the test should
be directed in the first place at those individuals likely
to be at high risk for HIV infection based on the pre-
sence of indicator situations or events where the esti-
mated prevalence of HIV-1 infection is above 1%, and at
the most vulnerable groups [42-44].
Among the limitations of this study, we highlight the
number of cases without data on lymphocyte count
(14.7%) with a different distribution in the case of the
IDU, which may lead to underestimation of the results
for this group in our study. Another limitation could be
the under-reporting of HIV infection due to the fact
that this was voluntary. This underreporting is estimated
around 15%-20% (unpublished data).
Conclusion
In conclusion, late presentation of HIV is common in
spite of a strong commitment to universal access to
HIV infection prevention, diagnosis and treatment in
our city. This study reveals a need to develop interven-
tions that increase HIV testing and facilitate earlier
entry into care, such as routine screening in healthcare
and non-clinical settings for patients at risk for HIV (e.
g. have unprotected sex with many sex partners, have a
sexually transmitted infection, have a diagnosis of tuber-
culosis, use illegal injected drugs, pregnancy). An accu-
rate sexual history and other risk factors, together with
knowledge of country of birth, can identify most indivi-
duals who should be offered an HIV test and a link to
care.
Abbreviations
ART: antiretroviral therapy; CI: confidence interval; HIV: human
immunodeficiency virus; HT: heterosexual relationships; HTw: heterosexual
women; HTm: heterosexual men; IDU: injecting drug users; IDUw: injection
drug use women; IDUm: injection drug use men; late presenters (LP):
persons presenting for care with a CD4 count below 350 cells/ml or
presenting with an AIDS-defining event at the time of HIV diagnosis or
within 3 months of the HIV-positive test, regardless of the CD4 cell count;
MSM: sex between men; OR: odds ratio; TB: tuberculosis.
Acknowledgements
We would like to thank to Dr. Joan R Villalbí, epidemiologist of Agència de
Salut Pública de Barcelona, for their valuable comments.
Members of the HIV Surveillance Group: Roser Clos, Pilar Gorrindo
(Agència de Salut Pública de Barcelona); Mercè Gurguí, Maria G Mateo, Maria
M Gutiérrez, Josep Cadafalch (Hospital de la Santa Creu i Sant Pau.
Universitat Autònoma de Barcelona); Vicenç Falcó (Hospital Vall de Hebron.
Universitat Autònoma de Barcelona);Teresa Carbonell (Hospital Universitari
del Mar); José I Pérez, Felipe García, José L Blanco, Esteban Martínez, Josep
Mallolas, Josep M Gatell (Hospital Clinic-IDIBAPS. University of Barcelona).
Author details
1Epidemiology Service. Agencia de Salut Pública de Barcelona, Barcelona,
Spain.
2Consorcio de Investigación Biomédica en Red de Epidemiología y
Salud Pública (CIBERESP.
3Hospital Clinic-IDIBAPS. University of Barcelona,
Barcelona, Spain.
4Infeccious Diseases Unit, Hospital de la Santa Creu i Sant
Pau. Universitat Autònoma de Barcelona, Barcelona, Spain.
5Infectious
Diseases, Hospital Vall de Hebron. Universitat Autònoma de Barcelona,
Barcelona, Spain.
6Internal Medicine-Infectious Diseases, Hospital del Mar,
Barcelona, Spain.
7Direcció General de Serveis Penitenciaris i de Rehabilitació.
Departament de Justícia. Barcelona, Spain.
8Escuela Nacional de Sanidad,
Instituto de Salud Carlos III, Madrid, Spain.
Authors’ contributions
PGdeO, JAC designed the study, interpreted the data, and drafted the
manuscript. PGdeO and MJB analysed the data. CM, MAS, IO, HK, VH, PD, ER,
AG, AM, JMM and the HIV Surveillance Group collected data and notified
the cases, and participated in writing and revised critically the manuscript.
All authors have reviewed and approved the final manuscript.
Competing interests
The authors declare that they have not competing interests.
Received: 18 April 2011 Accepted: 6 July 2011 Published: 6 July 2011
References
1. Adler A, Mounier-Jack S, Coker RJ: Late diagnosis of HIV in Europe:
definitional and public health challenges. AIDS Care 2009, 21:284-293.
2. Hamers FF, Phillips AN: Diagnosed and undiagnosed HIV-infected
populations in Europe. HIV Med 2008, 9(Suppl 2):6-12.
3. Oliva J, Galindo S, Vives N, Arrillaga A, Izquierdo A, Nicolau A, Castilla J,
Lezaun ME, Alvarez M, Rivas A, Díez M: Delayed diagnosis of HIV infection
in Spain. Enferm Infecc Microbiol Clin 2010, 28:583-589.
4. World Health Organization: Report of the Meeting on Criteria for HIV
Screening Programes [WHO/SPA/GLO/87.2]. Geneva:WHO; 1987 [http://
whqlibdoc.who.int/hq/1987/WHO_SPA_GLO_87.2_spa.pdf], Accessed
January 2011.
5. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB,
Clark JE: Centers for Disease Control and Prevention (CDC). Revised
recommendations for HIV testing of adults, adolescents, and pregnant
women in health-care settings. MMWR Recomm Rep 2006, 55(RR-14):1-17.
6. Secretaría del Plan Nacional sobre el Sida. Infección por VIH y SIDA: Plan
Multisectorial 2008-2012. Ministerio de Sanidad y Consumo. Madrid 2008
[http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/
PMS200812.pdf], Accessed January 2011.
7. Attia S, Egger M, Muller M, Zwahlen M, Low N: Sexual transmission of HIV
according to viral load and antiretroviral therapy: systematic review and
meta-analysis. AIDS 2009, 23:1397-1404.
8. Marks G, Crepaz N, Senterfitt JW, Janssen RS: Meta-analysis of high-risk
sexual behavior in persons aware and unaware they are infected with
HIV in the United States: implications for HIV prevention programs. J
Acquir Immune Defic Syndr 2005, 39:446-453.
9. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA,
Aschman DJ, Holmberg SD: Declining morbidity and mortality among
patients with advanced human immunodeficiency virus infection. HIV
Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
10. Sobrino-Vegas P, García-San Miguel L, Caro-Murillo AM, Miró JM, Viciana P,
Tural C, Saumoy M, Santos I, Sola J, del Amo J, Moreno S, CoRIS: Delayed
diagnosis of HIV infection in a multicenter cohort: prevalence, risk
factors, response to HAART and impact on mortality. Curr HIV Res 2009,
7:224-230.
11. Weinhardt LS, Carey MP, Johnson BT: Effect of HIV counseling and testing
on sexual behavior: a meta-analytic review of published research, 1985-
1997. Am J Pub Health 1999, 89:1397-1410.
12. Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D,
Malow R, McClellan WM: Behavioral interventions to reduce risk for
sexual transmission of HIV among men who have sex with men.
Cochrane Database Syst Rev 2008, 3:CD001230.
13. Marks G, Crepaz N, Janssen RS: Estimating sexual transmission of HIV from
persons aware and unaware that they are infected with the virus in the
USA. AIDS 2006, 20:1447-1450.
14. Fleishman JA, Yehia BR, Moore RD, Gebo KA, HIV Research Network: The
economic burden of late entry into medical care for patients with HIV
infection. Med Care 2010, 48:1071-1079[http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3022268/pdf/nihms-262526.pdf], Accessed February 2011.
15. Velasco M, Losa JE, Espinosa A, Sanz J, Gaspar G, Cervero M, Torres R,
Condes E, Barros C, Castilla V: Economic evaluation of assistance to HIV
patients in a Spanish hospital. Eur J Intern Med 2007, 18:400-404.
de Olalla et al. AIDS Research and Therapy 2011, 8:22
http://www.aidsrestherapy.com/content/8/1/22
Page 6 of 716. Krentz HB, Gill J: Despite CD4 cell count rebound the higher initial costs
of medical care for HIV-infected patients persist 5 years after
presentation with CD4 cell counts less than 350 μl. AIDS 2010,
24:2750-2753.
17. Romaguera A, Binefa G, Casabona J, García de Olalla P, Caylà J, Camps N,
Company M, Minguell S, Godoy P, Sala MR, Humet V, Alvarez J, Barrabeig I,
Grupo de médicos coordinadores de VIH/sida: Reporting of newly
diagnosed HIV infections in Catalonia, Barcelona, Spain. Implementation
and results. Gac Sanit 2005, 19:356-362.
18. Commission decision of 28/IV/2008 amending Decision 2002/253/EC
laying down case definitions for reporting communicable diseases to
the Community network under Decision No 2119/98/EC of the European
Parliament and of the Council. Acquired Immunodeficiency Virus (AIDS) and
Human Immunodeficiency Virus (HIV) Infection [http://www.ecdc.europa.eu/
en/healthtopics/spotlight/Documents/
080428_amending_desicion_Decision_2002-253-EC_on_case%20definitions.
pdf], Accessed February 2011.
19. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, Girardi E,
Johnson M, Kirk O, Lundgren J, Mocroft A, D’Arminio Monforte A, Phillips A,
Raben D, Rockstroh JK, Sabin C, Sönnerborg A, De Wolf F, European Late
Presenter Consensus Working Group: Late presentation of HIV infection: a
consensus definition. HIV Med 2011, 12:61-64.
20. 23750 LEY ORGÁNICA 15/1999, de 13 de diciembre, de Protección de
Datos de Carácter Personal. BOE núm. 298. 1999, 43088-43097[http://
www.boe.es/boe/dias/1999/12/14/pdfs/A43088-43099.pdf], Accessed
February 2011.
21. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, Rubio R,
Riera M, Viciana P, López Aldeguer J, Iribarren JA, de los Santos-Gil I,
Gómez-Sirvent JL, Berenguer J, Gutiérrez F, Saumoy M, Segura F, Soriano V,
Peña A, Pulido F, Oteo JA, Leal M, Casabona J, del Amo J, Moreno S, Grupo
de trabajo de la Cohorte de la Red de Investigación en Sida (CoRIS):
Spanish cohort of naïve HIV-infected patients (CoRIS): rationale,
organization and initial results. Enferm Infecc Microbiol Clin 2007, 25:23-31.
22. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA,
Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ,
Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR,
Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ,
Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD:
Late presentation for human immunodeficiency virus care in the United
States and Canada. Clin Infect Dis 2010, 50:1512-1520.
23. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F,
Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC,
Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C,
Staszewski S, Egger M, Cole SR: Timing of initiation of antiretroviral
therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of
18 HIV cohort studies. Lancet 2009, 373:1352-1363.
24. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A,
Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P,
Richman DD, Volberding PA, Yeni P, Schooley RT: Antiretroviral treatment
of adult HIV infection: 2010 recommendations of the International AIDS
Society-USA panel. JAMA 2010, 304:321-333.
25. Panel de expertos de Gesida y Plan Nacional sobre el Sida:
Recomendaciones de GESIDA/Plan Nacional sobre el Sida infectados por
el virus de la inmunodeficiencia humana (Actualización enero 2010).
Enferm Infecc Microbiol Clin 2010, 28:362-391.
26. European AIDS Clinical Society: Treatment guidelines (EACS).[http://www.
europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacs-
euroguidelines_fullversion.pdf], Accessed March 2011.
27. Antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M,
Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD,
Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F,
Sterne JA, Costagliola D: Prognosis of patients treated with cART from 36
months after initiation, according to current and previous CD4 cell
count and plasma HIV-1 RNA measurements. AIDS 2009, 23:2199-2208.
28. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A,
Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ,
Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J,
Sterne JA, Antiretroviral Therapy Cohort Collaboration: Effect of baseline
CD4 cell counts on the clinical significance of short-term immunologic
response to antiretroviral therapy in individuals with virologic
suppression. J Acquir Immune Defic Syndr 2009, 52:357-363.
29. Borghi V, Girardi E, Bellelli S, Angeletti C, Mussini C, Porter K, Esposito R:
Late presenters in an HIV surveillance system in Italy during the period
1992-2006. J Acquir Immune Defic Syndr 2008, 49:282-286.
30. Centers for Disease Control and Prevention (CDC): Vital signs: HIV testing
and diagnosis among adults–United States, 2001-2009. MMWR Morb
Mortal Wkly Rep 2010, 59:1550-1555.
31. Blanco JR, Caro AM, Pérez-Cachafeiro S, Gutiérrez F, Iribarren JA, González-
García J, Ferrando-Martínez S, Navarro G, Moreno S: HIV Infection and
Aging. AIDS Rev 2010, 12:218-230.
32. Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ,
Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ,
Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD,
Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J,
Rachlis A, Moore RD, Justice AC, for the North American AIDS Cohort
Collaboration on Research and Design: CD4 count at presentation for HIV
care in the United States and Canada: Are those over 50 years more
likely to have a delayed presentation? AIDS Res Ther 2010, 7:45[http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC3022663/pdf/1742-6405-7-45.pdf],
Accessed March 2011.
33. Manavi K, McMillan A, Ogilvie M, Scott G: Heterosexual men and women
with HIV test positive at a later stage of infection than homo- or
bisexual men. Int J STD AIDS 2004, 15:811-814.
34. Centers for Disease Control and Prevention (CDC): Late versus early testing
of HIV–16 Sites, United States, 2000-2003. MMWR 2003, 52:581-586.
35. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, Prinz B,
Youle M, Johnson MA: Late presenters in the era of highly active
antiretroviral therapy: uptake of and responses to antiretroviral therapy.
AIDS 2004, 18:2145-2151.
36. Castelnuovo B, Chiesa E, Rusconi S, Adorni F, Bongiovanni M, Melzi S,
Cicconi P, Tordato F, Meroni L, Bini T, d’Arminio Monforte A: Declining
incidence of AIDS and increasing prevalence of AIDS presenters among
AIDS patients in Italy. Eur J Clin Microbiol Infect Dis 2003, 22:663-669.
37. Hibbard JH, Pope CR: Gender roles, illness orientation and use of medical
services. Soc Sci Med 1983, 17:129-137.
38. Girardi E, Aloisi MS, Arici C, Pezzotti P, Serraino D, Balzano R, Vigevani G,
Alberici F, Ursitti M, D’Alessandro M, d’Arminio Monforte A, Ippolito G, for
the ICoNA Behavioural Epidemiology Study Group: Delayed presentation
and late testing for HIV: demographic and behavioral risk factors in a
multicenter study in Italy. J Acquir Immune Defic Syndr 2004, 36:951-959.
39. Ndiaye B, Salleron J, Vincent A, Bataille P, Bonnevie F, Choisy P, Cochonat K,
Fontier C, Guerroumi H, Vandercam B, Melliez H, Yazdanpanah Y: Factors
associated with presentation to care with advanced HIV disease in
Brussels and Northern France: 1997-2007. BMC Infect Dis 2011, 11:11
[http://www.biomedcentral.com/content/pdf/1471-2334-11-11.pdf],
Accessed March 2011.
40. Grigoryan A, Hall HI, Durant T, Wei X: Late HIV diagnosis and
determinants of progression to AIDS or death after HIV diagnosis
among injection drug users, 33 US States, 1996-2004. PLoS One 2009, 4:
e4445.
41. Larson BA, Brennan A, McNamara L, Long L, Rosen S, Sanne I, Fox MP: Lost
opportunities to complete CD4+ lymphocyte testing among patients
who tested positive for HIV in South Africa. Bull World Health Organ 2010,
88:675-680.
42. Gatell JM, Zulaica D, del Romero J, Robledo T: Cómo promover y facilitar
el diagnóstico precoz de la infección por el VIH-1. Enf Emerg 2010,
12:121-124.
43. Girardi E, Sabin CA, Monforte AD: Late diagnosis of HIV infection:
epidemiological features, consequences and strategies to encourage
earlier testing. J Acquir Immune Defic Syndr 2007, 46(Suppl 1):S3-S8.
44. Delpierre C, Cuzin L, Lauwers-Cances V, Marchou B, Lang T: High-Risk
groups for late diagnosis of HIV infection: a need for rethinking testing
policy in the general population. AIDS Patient Care STDS 2006, 20:838-847.
doi:10.1186/1742-6405-8-22
Cite this article as: de Olalla et al.: Epidemiological characteristics and
predictors of late presentation of HIV infection in Barcelona (Spain)
during the period 2001-2009. AIDS Research and Therapy 2011 8:22.
de Olalla et al. AIDS Research and Therapy 2011, 8:22
http://www.aidsrestherapy.com/content/8/1/22
Page 7 of 7